Michael Jos. Campbell
First SEC filing: Sept. 26, 2019 · Latest: Sept. 26, 2019
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2023 | IVF | A | 83,000 | · | · | 83,000 Direct | · | Acquired | (price as of 2026-10-05) |
| June 1, 2022 | IVF | P | 10,526 | $0.95 | $10,000 | 75,762 Direct | +16.14% | Acquired | -100.0% (price as of 2026-10-05) |
| Jan. 15, 2022 | IVF | A | 15,236 | · | · | 65,236 Direct | +30.47% | Acquired | (price as of 2026-10-05) |
| Jan. 15, 2022 | IVF | A | 18,513 | · | · | 18,513 Direct | · | Acquired | (price as of 2026-10-05) |
| Dec. 31, 2020 | IVF | A | 165,000 | · | · | 165,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Feb. 5, 2020 | IVF | A | 99,112 | · | · | 99,112 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 17, 2020 | IVF | A | 4,000,000 | · | · | 4,000,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 17, 2020 | IVF | A | 1,000,000 | · | · | 1,607,800 Direct | +164.53% | Acquired | (price as of 2026-10-05) |
| Oct. 31, 2018 | IVF | A | 400,000 | $0.39 | $156,000 | 607,800 Direct | +192.49% | Acquired | -100.0% (price as of 2026-10-05) |
| Jan. 22, 2018 | IVF | A | 200,000 | $0.12 | $24,000 | 207,800 Direct | +2564.10% | Acquired | -100.0% (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| May 18, 2023 | IVF | Stock Option (right to buy) | Common Stock | $0.37 | May 17, 2033 | 83,000 | Acquired |
| Jan. 15, 2022 | IVF | Stock Option | Common Stock | $3.61 | Jan. 14, 2032 | 18,513 | Acquired |
| Dec. 31, 2020 | IVF | Stock Option | Common Stock | $3.06 | Dec. 31, 2030 | 165,000 | Acquired |
| Feb. 5, 2020 | IVF | Stock Option | Common Stock | $0.25 | Feb. 5, 2030 | 99,112 | Acquired |
| Jan. 17, 2020 | IVF | Stock Option | Common Stock | $0.21 | Jan. 17, 2030 | 4,000,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | $258,854 | · | · | · | · | · | · | $258,854 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.